Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Stoke Therapeutics' Cash from Financing Activities fell 6176.0% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 9592.66%. This contributed to the annual value of $131.1 million for FY2024, which is 14731.45% up from last year.
  • Per Stoke Therapeutics' latest filing, its Cash from Financing Activities stood at $3.1 million for Q3 2025, which was down 6176.0% from $554000.0 recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Cash from Financing Activities peaked at $120.6 million during Q2 2024, and registered a low of $43000.0 during Q4 2022.
  • Over the past 4 years, Stoke Therapeutics' median Cash from Financing Activities value was $1.7 million (recorded in 2024), while the average stood at $15.7 million.
  • In the last 5 years, Stoke Therapeutics' Cash from Financing Activities surged by 25125416.67% in 2024 and then crashed by 9954.08% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Cash from Financing Activities stood at $43000.0 in 2022, then skyrocketed by 16976.74% to $7.3 million in 2023, then plummeted by 92.26% to $568000.0 in 2024, then skyrocketed by 449.3% to $3.1 million in 2025.
  • Its Cash from Financing Activities was $3.1 million in Q3 2025, compared to $554000.0 in Q2 2025 and $1.4 million in Q1 2025.